OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Metabolism & Toxicology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	171
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	71
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance	68
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	57
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury	55
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	46
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	40
Therapeutic drug monitoring of letermovir in allogeneic hematopoietic cell transplant recipients: where are we?	37
Guidance for interactions between antiseizure medications	35
Hormones, microbes, and PrEP drugs in the female genital tract	33
Comorbidities and the right dose: antipsychotics	31
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	30
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas	29
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	27
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	27
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	27
Bioactivity descriptors for in vivo toxicity prediction: now and the future	26
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	25
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	25
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	24
A comprehensive review of the efficacy and safety of ertugliflozin	24
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	23
Correction	23
Pharmacokinetic evaluation of concizumab for the treatment of hemophilia	20
Impact of sex and gender medicine on antibiotic research and use: a narrative review of existing evidence	19

Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	18
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	18
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	18
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	18
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	17
Development and hepatotoxicity of rifamycin derivatives	17
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	17
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	17
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	17
Potential integration of multiple organs-on-a-chip for comprehensive drug–drug interaction prediction	17
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	17
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia	16
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	16
Exploring the influence of sex on idiosyncratic DILI: impact on risk assessment	15
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	15
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	15
Pregnancy and epilepsy: pharmacokinetic insights into antiseizure medications	14
Population pharmacokinetic–pharmacodynamic analysis of givinostat	14
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	14
Clinically significant interactions between drugs, microbiome, and sex	14
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	14
Risk factors and prediction for DILI in clinical practice	14
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	13
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	13
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	13
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	13
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	13
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	13
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	12
Understanding pharmacokinetic variability in women across different life stages	12
Interactions between phytotherapeutics and chemotherapeutics: the current evidence	12
Rivaroxaban vs. apixaban in short bowel syndrome: a focused clinical pharmacology review	12
Practical perspectives on addressing hepatotoxicity during clinical candidate selection	12
PBPK models of the female reproductive tract: current and future analysis	11
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	11
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	11
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	11
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	11
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	11
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	11
Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the ‘exposome’ and human health	10
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	10
An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications	10
Pharmacokinetics of apixaban in patients with short bowel syndrome: a Bayesian re-estimation approach	10
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	10
Sex differences and impact of age-based menopausal status on tacrolimus pharmacokinetics: results of the TransplantLines Biobank and Cohort study	10
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	10
Switching from cangrelor to oral P2Y ₁₂ inhibitors: a focused review on drug–drug interactions	10
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	10
Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far	10

Overcoming barriers to machine learning applications in toxicity prediction	10
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	9
Drug interactions in people with HIV treated with antivirals for other viral illnesses	9
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	9
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	9
Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment	9
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	9
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	9
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	9
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	9
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	9
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	9
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	9
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	9